EuPRAXIA-DN Fellow David Gregocki presents research at Tuscany Health Ecosystem - Spoke 1 Conference

Radiotherapy plays a crucial role in the treatment of many cancers, with over half of oncology patients receiving this therapy. However, recent research highlights the need to advance beyond traditional methods, focusing on innovative radiation delivery techniques to enhance clinical outcomes.

The Tuscany Health Ecosystem (THE) subproject Spoke 1 models and experiments with innovative approaches to radiotherapy and oncology diagnostics, such as the revolutionary FLASH radiotherapy and new theranostic radiopharmaceuticals, with prospects for clinical implementation in the treatment of radioresistant tumors and a reduction in side effects and treatment times. Spoke 1 includes preclinical studies and clinical validation, with implications in sectors such as photonics, hospital accelerators, dosimetry, and software for treatment plans.

The 2024 Tuscany Health Ecosystem - Spoke 1: Advanced Radiotherapies and Diagnostics in Oncology conference, was held last December at CNR-INO in Pisa. The meeting provided an opportunity to reflect on the progress made and share the results of research activities, ranging from the use of innovative technologies in radiotherapy to the application of new radiopharmaceuticals and radiotracers for more precise and targeted diagnosis.

David during his presentation at the Spoke 1 conference. Image credit: Dr Simona Piccinini, INO-CNR

EuPRAXIA-DN Fellow David Gregocki contributed to the conference with a presentation about correlation study between the electron charge measured by integrating current transformer and the lanex emission signal.

This conference brought together physicists, doctors, radio-oncologists, chemists, and biologists to discuss future prospects and new projects within Spoke 1, which aims to continue integrating the best innovations in the field of radiotherapy and oncological diagnostics.